Rems-Murr-Kliniken gGmbH — Clinical Trial Site

10 Registered trials

5 Currently recruiting

Organisation

Rems-Murr-Kliniken gGmbH

Location

Winnenden, Germany

Identifier

ORG-100034420

Address

Am Jakobsweg 1, 71364, Germany

Departments

Breast Center
Hämatologie, Onkologie und Palliativmedizin
Hämatologie, Onkologie und Palliativmedizin
Klinik für Gynäkologie und Geburtshilfe
Klinik für Hämatologie, Onkologie
Klinik für Hämatologie, Onkologie und Palliativmedizin
Oncology
Rems-Murr-Kliniken gGmbH

Clinical trials at this site (10)

Search interface

A study to evaluate the efficacy of oxaliplatin- or gemcitabine-based chemotherapy after allocation by standard criteria or by genetic marke… Pending

2024-514682-19-00 Resected pancreatic ductal adenocarcinoma 5
Pre-Operative Treatment in rEseCTable cOlon canceR (PROTECTOR/FIRE-10; AIO-KRK-0620; IAG-VO-0323) Prospective, randomized, open-label, multi… Recruiting

2023-508076-11-00 Colon cancer staged T3-4 and/or nodal positive by CT an 5 2025-04-01
Phase II study evaluating the addition of elacestrant, an oral selective estrogen receptor degrader (SERD), to standard-of-care olaparib in … Recruiting

2023-504925-38-00 patients with hormone receptor (HR)-positive, HER2-nega 4 2024-12-10
An international, multicenter, randomised, superiority phase III, open label, 2-arm study to investigate distant metastasis free survival wi… Recruiting

2022-501453-36-00 Breast cancer 5 2024-02-23
CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCE… Recruiting

2022-500764-35-00 Patients with advanced HER2-negative, hormone receptor 6 2022-10-13
Midostaurin + Gemtuzumab Ozogamicin combination in first-line standard therapy for acute myeloid leukemia (MOSAIC) Recruiting

2024-514014-13-00 female and male adult patients with acute myeloid leuke 9 2020-09-02
A Phase II, single-arm trial of Atezolizumab/Platinum/Etoposide for the treatment of advanced large-cell neuroendocrine cancer of the lung (… Ended

2024-515902-15-00 Male and female adult patients with locally advanced or 4 2022-01-18
Daratumumab for first line treatment of transplant-ineligible myeloma patients followed by daratumumab re-treatment at first relapse (GMMG-D… Ended

2024-517761-17-00 Multiple Myeloma 4 2021-05-31
A randomized phase III trial assessing the benefit of the addition of isatuximab to lenalidomide / bortezomib / dexamethasone (RVd) inductio… Ended

2024-513464-26-00 Multiple Myeloma 5 2018-10-18
CIRCULATE Ended

2023-506715-18-00 colon cancer stage II, rectal cancer stage II 5 2019-12-04